News | February 28, 2026
Eli Lilly and Incyte score key win for teens with severe alopecia areata in Europe
AA, a chronic immune disease, can cause extensive and unpredictable hair loss
AA, a chronic immune disease, can cause extensive and unpredictable hair loss
Arcellx develops innovative immunotherapies for cancer and other incurable diseases
Sodium Phosphates Injection is indicated as a source of phosphorus, for addition to large volume intravenous fluids, to prevent or correct hypophosphatemia in patients with restricted or no oral intake
The move follows encouraging Phase I data and a series of regulatory wins from the U.S. Food and Drug Administration
BLA is based on a robust data package supporting similarity to Orencia (abatacept) IV for infusion through totality of evidence including pharmacokinetic (PK) data
If approved, TEV-'749 could help address a significant unmet need in available schizophrenia treatment options by addressing the lack of viable long-acting olanzapine formulations
The approval, based on results from the Phase 3 AMPLIFY trial, marks the first all-oral, fixed-duration regimen for first-line CLL therapy
The results mark a potential breakthrough for patients living with CIndU, a condition with limited treatment options
Bosentan 32 mg tablets for oral suspension are indicated for the treatment of Pulmonary Arterial Hypertension
The Pre-Approval Inspection (PAI) was completed on February 13, 2026, and the company is initiating corrective actions.
Subscribe To Our Newsletter & Stay Updated
